Date | Name | Shares | Transaction | Value |
May 21, 2025
| Oluyemi Okupe Chief Financial Officer |
113,816
| Open market or private sale of non-derivative or derivative security Non-derivative transaction at $60.22 per share |
6,853,999.52
|
May 21, 2025
| Oluyemi Okupe Chief Financial Officer |
125,397
| Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $5.01 per share |
628,238.97
|
May 21, 2025
| Nader Kabbani Chief Operating Officer |
216,333
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|
May 21, 2025
| Oluyemi Okupe Chief Financial Officer |
124,849
| Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $11.53 per share |
1,439,508.97
|
May 21, 2025
| Oluyemi Okupe Chief Financial Officer |
58,443
| Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
0.00
|
May 21, 2025
| Oluyemi Okupe Chief Financial Officer |
398,748
| Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
0.00
|
Apr 8, 2025
| Melissa Baird Chief Operating Officer |
805,083
| Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $5.01 per share |
4,033,465.83
|
Apr 8, 2025
| Melissa Baird Chief Operating Officer |
1,581,288
| Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
0.00
|
Apr 7, 2025
| Irene A. Becklund PAO |
8,007
| Open market or private sale of non-derivative or derivative security Non-derivative transaction at $28.78 per share |
230,441.46
|
Apr 2, 2025
| Soleil Boughton Chief Legal Officer |
170,285
| Open market or private sale of non-derivative or derivative security Non-derivative transaction at $27.77 per share |
4,728,814.45
|
Mar 28, 2025
| Melissa Baird Chief Operating Officer |
751,243
| Open market or private sale of non-derivative or derivative security Non-derivative transaction at $37.35 per share |
28,058,926.05
|
Mar 28, 2025
| Melissa Baird Chief Operating Officer |
755,928
| Open market or private sale of non-derivative or derivative security Non-derivative transaction at $36.6 per share |
27,666,964.80
|
Mar 28, 2025
| Melissa Baird Chief Operating Officer |
759,169
| Open market or private sale of non-derivative or derivative security Non-derivative transaction at $35.37 per share |
26,851,807.53
|
Mar 28, 2025
| Melissa Baird Chief Operating Officer |
54,556
| Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
0.00
|
Mar 28, 2025
| Melissa Baird Chief Operating Officer |
781,727
| Open market or private sale of non-derivative or derivative security Non-derivative transaction at $34.5 per share |
26,969,581.50
|
Mar 14, 2025
| Irene A. Becklund PAO |
22,284
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|
Mar 14, 2025
| Andrew Dudum Chief Executive Officer; Director |
306,406
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|
Mar 7, 2025
| Christiane Pendarvis Director |
11,417
| Open market or private sale of non-derivative or derivative security Non-derivative transaction at $40 per share |
456,680.00
|
Mar 6, 2025
| Patrick Carroll Chief Medical Officer; Director |
56,529
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|
Mar 6, 2025
| Mike Chi Chief Commercial Officer |
169,587
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|